Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) is a clinical-stage pharmaceutical company developing certepetide-based therapies for advanced solid tumors and other serious diseases. This news page aggregates company announcements, clinical trial updates and regulatory disclosures so readers can follow how Lisata’s certepetide program and related partnerships evolve over time.
Lisata’s recent news flow has focused on progress across multiple certepetide clinical studies, including the ASCEND Phase 2b trial in metastatic pancreatic ductal adenocarcinoma, the BOLSTER Phase 2a trial in cholangiocarcinoma, the CENDIFOX Phase 1b/2a trial in pancreatic, colon and appendiceal cancers, the iLSTA Phase 1b/2a trial in locally advanced non-resectable pancreatic ductal adenocarcinoma and a Phase 2a glioblastoma multiforme study. Press releases have highlighted preliminary efficacy and safety signals, tumor microenvironment findings and timelines for upcoming data readouts.
Investors and researchers can also see updates on Lisata’s business development activities, such as its global non-exclusive license agreement with Catalent, Inc. to use certepetide as a SMARTag® antibody-drug conjugate payload, and its strategic alliance with GATC Health to apply an AI-powered Multiomics Advanced Technology™ platform to drug discovery. Financial results releases provide context on operating expenses, cash runway and the company’s ability to support ongoing trials.
By reviewing the LSTA news feed on this page, readers can monitor clinical milestones, conference presentations, licensing developments and other corporate communications directly sourced from Lisata’s public announcements and related SEC-referenced materials.
Lisata Therapeutics, a clinical-stage pharmaceutical company, will announce its financial results for Q3 2022 on November 10, 2022, at 4:30 p.m. (ET). The company is focused on developing therapies for advanced solid tumors. Its lead product, LSTA1, aims to enhance the delivery of anti-cancer drugs by modifying the tumor microenvironment. Clinical trials have shown LSTA1 to be safe and effective for pancreatic cancer treatment. Lisata’s technology platform also supports autologous CD34+ cell therapy programs.
Lisata Therapeutics (Nasdaq: LSTA) announced its participation in two significant events: the RNA USA Leaders Congress on October 18-19, 2022, where David S. Slack will join a keynote panel, and the LD Micro Main Event XV Conference on October 25-27, 2022, featuring a presentation by CEO David J. Mazzo. Lisata is focused on developing therapies for advanced solid tumors, with its lead candidate LSTA1 showing promise in enhancing chemotherapy delivery for pancreatic cancer. The company also investigates other therapies through its CD34+ cell technology platform.
Lisata Therapeutics (Nasdaq: LSTA) announced that Erkki Ruoslahti, M.D., Ph.D., has received the 2022 Albert Lasker Basic Medical Research Award. Recognized for his discovery of integrins, Ruoslahti's work underpins the CendR Platform™, which enhances drug delivery to solid tumors. The CendR platform is central to Lisata's lead clinical program, LSTA1, targeting advanced solid tumors. Ruoslahti's accolades highlight significant contributions to medical science, including over 150 patents. Lisata focuses on developing therapies for challenging cancers, leveraging Ruoslahti's expertise.